Press Release EU ZA

Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom

Published

8 months ago

February 12, 2023

admin

Avextra successfully exported EU-GMP standardised cannabis extracts manufactured in its German facility to its distribution partner in the United Kingdom

Export is a significant milestone that validates the regulatory pathway for medical cannabis products from Germany

Avextra will continue to work with its partners to serve patients across the United Kingdom and across Continental Europe

Avextra retains an ownership stake in Integro Medical Clinics in London, as a strategic asset in the UK market

BENSHEIM, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading vertically-integrated manufacturer of Cannabis-based medicines located in Germany, is pleased to announce the successful export of its standardised cannabis extracts to the United Kingdom (“UK”). The UK is the world’s largest exporter of Cannabis-based medicines and therefore one of the strictest jurisdictions in the world for their imports.

This milestone marks a significant step forward for the Company as it validates the regulatory pathway for the UK market and provides patients access to Avextra’s EU-GMP certified Cannabis-based medicines.

The Company’s standardised cannabis extracts, which are manufactured using the highest quality starting material and the latest extraction techniques, have been met with positive feedback from patients and healthcare professionals alike. Avextra’s commitment to producing safe and effective products has been recognised by regulatory bodies, allowing the company to enter new markets and reach more patients in need.

Avextra has an ownership stake in Integro Medical Clinics, a medical cannabis clinic located in London, UK. This clinic provides Avextra the opportunity to better understand unmet patient need and gather valuable insights to develop safe and effective Cannabis-based medicines of the highest quality to address it. This unique combination of distribution and market intelligence has put Avextra in a strong position to continue to grow and succeed in the UK and other European medical cannabis markets.

“We are thrilled to be able to expand our reach and bring our products to patients in the UK,” said Bernhard Babel, Co-CEO of Avextra. “Regulations are developing in a positive direction across Europe as governments and the medical community continue to recognise the benefits of medical cannabis and its potential to improve patients’ quality of life”. In addition, “Having a stake in Integro Medical Clinics allows us to aggregate data and glean valuable insights into the needs of patients in the UK, as we continue to innovate and improve our products to meet those needs.”

This expansion into the UK market is a testament to Avextra’s commitment to innovation and quality, and the company looks forward to continued growth and to bringing its products to more patients across Europe in the future.

About Avextra AG

Avextra is one of Europe’s leading vertically integrated suppliers of high-quality Cannabis-based medicines. Founded in 2019 and based out of Bensheim, Germany, the company focuses on the production of precisely formulated Cannabis-based medicines. Avextra controls the entire value chain – from the cultivation of the plants in Portugal to the EU-GMP certified production in Germany. Avextra operates across continental Europe through an expansive distribution network and assets strategically developed in key markets.

Learn more at avextra.com and stay up to date at LinkedIn: company/Avextra-ag/.

Source link

Press Release EU ZA

Press Release: Lyphe Group and Boveda INC. Forge Partnership for UK Medical Cannabis Patients

Published

2 weeks ago

September 14, 2023

admin

Lyphe Group (“Lyphe”), one of the UK’s leading medical cannabis companies, is pleased to announce an innovative partnership set to enhance the way patients receive their medical cannabis prescriptions.

In an industry first, Lyphe’s dispensing pharmacy Dispensary Green has partnered with Boveda Inc. (“Boveda”), the global leader in 2-way humidity control, to empower patients to keep their cannabis prescriptions in optimal condition.

As part of the partnership, Dispensary Green will include complimentary Boveda packs with all medical cannabis flower prescriptions. Dispensary Green and Boveda will also work together to educate patients on how to preserve the freshness of their medication and identify key quality markers.

Nick Pateras, CEO of Lyphe Group, said: “This partnership exemplifies our commitment to supporting patients’ rights for the highest quality medical cannabis.

“Our ambition to deliver a best-in-class patient experience has led us to identify several opportunities for standout patient care, and our relationship with Boveda is the first of these initiatives. We understand the importance of patients’ medicine being at its freshest and most effective for the conditions they are treating.”

Benjamin Patock, Head of International Relations at Boveda Inc., adds: “Proper humidification is one of the most pressing global challenges in cannabis care today, especially since it extends beyond the point of sale into patients’ homes – and therefore beyond the direct control of producers, clinics, and pharmacies.

“It is a pleasure to see medicinal pioneers such as Lyphe Group taking this extra step towards a flawless patient experience by embracing our patented technology. We are looking forward to a great partnership!”

Source link

Press Release EU ZA

ElixinolSkin cosmetics return to UK

Published

6 months ago

April 7, 2023

admin

Acclaimed Global CBD brand, Elixinol, is making a highly anticipated return to the UK market thanks to a partnership with BRITISH CANNABIS™.

This exciting development was made possible by the 2022 licensing and distribution agreement entered into with BRITISH CANNABIS™ a leading UK-based company.

With this strategic partnership in place, customers in the UK can look forward to experiencing the exceptional quality and purity of Elixinol’s CBD products, which have been meticulously crafted using the finest ingredients and industry-leading production techniques.

“As the trusted regional partner of Elixinol, we are thrilled to be able to bring you a range of cosmetics that not only enhances your skin’s natural radiance but also promotes overall well-being”, commented BRITISH CANNABIS™ Marketing Director, Steve Batchelor.

New partnership sees revamped ElixinolSkin cosmetics return to UK

Source link

Press Release EU ZA

CiiTECH Bought Out Of Administration By Fellow UK Company For £210,00

Published

6 months ago

April 7, 2023

admin

CBD company CiiTECH has been sold to fellow UK-based cannabis company Tenacious Labs for £210,000.

In July 2021 CiiTECH raised £2.1m to fund its listing on the London Stock Exchange with a slated value of £17.5m.

However, after two loss-making years it fell into administration on October 22, 2022, and on February 16, this year, it was sold to Tenacious Halfway – a subsidiary of Tenacious Labs – for £210,000.

Administrators Leonard Curtis said it had received 46 expressions of interest in buying the assets of the business, which resulted in five offers with Tenacious making the highest bid.

Nick Morland, CEO and co-founder of Tenacious Labs, told Business of Cannabis: “CiiTECH was in the same situation as a couple of dozen good businesses. The irony is that they got hit the hardest as they were busy on the next step (an LSE listing).

Source link